Method for reducing side effects of CB2 receptor agonist therapy using a combination of a selective CB2 receptor agonist and a selective CB1 receptor antagonist
AssigneeAbbott Laboratories
InventorWilliam A. Carroll
Life of this patent
Estimating the term…
Abstract
The present application describes a method of treating pain with a combination of a CB2 cannabinoid receptor agonist and rimonabast.
Claims5
A method for treating a subject suffering from pain using a combination therapy comprising administering a selective CB2 receptor agonist selected from the group consisting of (Z)—N-(5-tert-butyl-3-butylthiazol-2(3H)-ylidene)-5-chloro-2-methoxybenzamide and (Z)—N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropanecarboxamide in an amount effective to obtain a therapeutic effect, and rimonabant in an amount effective to block any adverse effects mediated by the CB1 receptor, but not to antagonize the therapeutic effect of the CB2 receptor agonist.
A composition comprising a selective CB2 receptor agonist selected from the group consisting of (Z)—N-(5-tert-butyl-3-butylthiazol-2(3H)-ylidene)-5-chloro-2-methoxybenzamide and (Z)—N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropanecarboxamide in an amount effective to produce a therapeutic effect, rimonabant in an amount effective to antagonize side and adverse effects produced by the CB2 agonist, but not to antagonize the therapeutic effect of the CB2 agonist, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.